Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (DAZALS)
2021-005611-31Phase 2Active
- Sponsor
- Corcept Therapeutics
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Dazucorilant with Placebo (2 arms). Primary endpoint: Primary Efficacy Endpoint. Started Jun 2022; status: active.
02
Drugs
dazucorilant
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2021-005611-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005611-31.